Hyperfine

Hyperfine, Inc. is a medical device development company engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hyperfine reports Q4 revenue of $1.4M, eyes $14M revenue in 2023

Hyperfine's Q4 2022 earnings call highlighted financial performance, strategic achievements in 2022, challenges in net losses and expenses, and opportunities for revenue growth and expansion in 2023. The company's focus on innovation, partnerships, and commercial progress underpins its outlook for the coming year.

Hyperfine reports record revenue in Q1 2023, eyes U.S. expansion

Hyperfine's Q1 2023 performance reflects strong revenue growth and strategic advancements in FDA clearances and partnerships. While facing significant expenses and cash burn, the company maintains a positive outlook for revenue and growth opportunities through innovation and market expansion.

Hyperfine reports record revenue in Q2 2023 amidst strategic expansion

Hyperfine's Q2 2023 earnings call reflects strong revenue growth, strategic focus on critical care and pediatric markets, and ongoing investment in technology and clinical studies. Despite financial challenges, the company maintains a positive outlook with a clear roadmap for future growth. Managing expenses and cash burn while pursuing innovation will be key to sustainable success.

Hyperfine reports robust Q3 earnings, eyes market expansion opportunities

Hyperfine's Q3 performance showcased strong revenue growth and improved financial metrics.
The company's focus on innovation and collaborations presents opportunities for market expansion.
Challenges include balancing investments in clinical studies while maintaining financial stability.

Hyperfine reports strong revenue growth and innovation focus for 2024

Hyperfine's Q4 2023 performance reflects robust revenue growth, strategic expansion into prestigious institutions, and a focus on cutting-edge healthcare solutions.
While facing financial challenges and a net loss, the company's commitment to innovation, FDA clearances, and market opportunities position it for future success.
With a strong 2024 revenue guidance, Hyperfine is poised to leverage its achievements in 2023, customer success, and international expansion to drive growth and profitability.

Hyperfine reports strong Q1 revenue growth and advances in medical imaging

Hyperfine's Q1 2024 performance reflects revenue growth driven by international contributions and advancements in clinical programs and commercial expansion.
While facing financial challenges and cash burn, the company maintains a positive outlook with plans for future growth and innovation in medical imaging technology.
Strategic strengths in AI software development and clinical applications position Hyperfine well to capture opportunities in the healthcare market and drive revenue growth.

Hyperfine reports robust Q3 growth, eyes international expansion opportunities

Hyperfine's Q3 2024 performance reflects strong revenue growth and operational efficiency improvements.
The company's focus on innovation, clinical efficacy, and market expansion presents opportunities for sustained growth.
However, managing cash burn, meeting revenue targets, and navigating competitive pressures remain key challenges for Hyperfine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.

Hyperfine, Inc. (NASDAQ:HYPR ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Maria Sainz - President and CEO Brett Hale - Chief Administrative Officer and CFO Conference Call Participants Yuan Zhi - B. Riley Operator Good afternoon.

Hyperfine, Inc. (HYPR) Q3 2024 Earnings Call Transcript

Hyperfine, Inc. (HYPR) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago.

Hyperfine, Inc. (HYPR) Reports Q3 Loss, Tops Revenue Estimates

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update.

Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces CE approval of its latest generation of AI-powered Swoop® system software under the European Medical Device Regulation.

Hyperfine Announces European Launch with CE Approval

MADRID--(BUSINESS WIRE)--Hyperfine, Inc. announced the presentation of additional research data and images using the Swoop® system to image patients with Alzheimer's disease.

Hyperfine Announces Alzheimer's Research with Promising Swoop® System Data and Advanced Image Quality

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024.

Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024

Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.

HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?

GUILFORD, Conn.--(BUSINESS WIRE)--Investigators at Johns Hopkins Hospital and the University of Texas-Houston publish study using the Swoop® system for patients on ECMO support.

Hyperfine Swoop® Portable MR Imaging® System Utilized in Multicenter SAFE MRI ECMO Study Published in the September 29th Issue of Circulation

Compared to conventional MRI, which takes an average of 27.7 hours, the Swoop system of HYPR operates with a median time-to-scan of 2.5 hours.

Favorable Data on Swoop Portable MRI Likely to Support Hyperfine Stock

PARIS--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of interim data supporting the role portable ultra-low-field MRI can play in acute stroke workup in a hospital emergency department setting. The findings from the study, titled Interim Analysis from Single Centre Observational Study.

Hyperfine Announces Promising Interim Findings on the Value of Portable, Ultra-low-field MR Imaging for Acute Stroke Care

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a collaboration with the Medical University of South Carolina to assess the brains of astronauts before and after embarking on the Polaris Dawn mission. Researchers will utilize the Swoop® Portable MR Imaging® system at a SpaceX facility in.

Researchers to Monitor Astronaut Brain Health Using Images Acquired with the Hyperfine, Inc. Swoop® Portable MR Imaging® System

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. Members of management are scheduled to present on Monday, September 9, 2024, at 7:00 am ET. Management will also be hosting in-person meetings at the.

Hyperfine, Inc. to Participate in Upcoming Investor Conferences

Hyperfine, Inc. (NASDAQ:HYPR ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Yuan Zhi - B. Riley Operator Good afternoon, and welcome to Hyperfine's Second Quarter 2024 Earnings Conference Call.

Hyperfine, Inc. (HYPR) Q2 2024 Earnings Call Transcript

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates

PHILADELPHIA--(BUSINESS WIRE)--Hyperfine presents initial data from observational clinical studies evaluating the use of portable MR brain imaging for Alzheimer's patients.

Hyperfine Announces Presentation of Initial Data from Observational Clinical Studies Evaluating the Use of Portable MR Brain Imaging for Alzheimer's Patients

Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.

Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces FDA clearance of software update that enables faster acquisition of best-in-class ultra-low-field Brain Images.

Hyperfine Announces FDA Clearance of Software Update That Enables Faster Acquisition of Best-in-Class Ultra-Low-Field Brain Images

Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.

Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to announce second quarter 2024 financial results on August 8, 2024.

Hyperfine, Inc. to Announce Second Quarter 2024 Financial Results on August 8, 2024

Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.

Hyperfine (HYPR) Inks New Partnerships to Expand in Europe

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine expands European market reach with additional strategic distributor partners.

Hyperfine Expands European Market Reach with Additional Strategic Distributor Partners

GUILFORD, Conn.--(BUSINESS WIRE)--Clinical research using Swoop® system for Alzheimer's disease monitoring to be presented at the 2024 AAIC.

Clinical Research Using Swoop® System for Alzheimer's Disease Monitoring to be Presented at the 2024 Alzheimer's Association International Conference

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to host analyst and investor education webcast with clinical and brain imaging experts on June 25, 2024.

Hyperfine, Inc. to Host Analyst and Investor Education Webcast with Clinical and Brain Imaging Experts on June 25, 2024

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. continues global expansion by entering into distribution partnership with Radiosurgery Global, Ltd. to bring Swoop® system to India.

Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

PEDEVCO

If you have some spare change jingling in your pocket, it might be worth considering investing that money in penny stocks with good upside potential. The penny stocks on this list are each worth less than $1 as of writing, and I believe many of them could be multibaggers if the stars align favorably.

News for Hyperfine Stock (HYPR)